Ultragenyx Pharmaceutical Inc.
An insider at 1 company in coverage, as reported on Form 4. SEC CIK 1515673. Latest Form 4 filed Aug 12, 2021.
Roles
As stated on the filings: the relationship to the company and any officer title.
| Company | Role | Transactions | First | Latest |
|---|---|---|---|---|
| Arcturus Therapeutics Holdings Inc.ARCT | Director | 2 | 2021-08-10 | 2021-08-11 |
| Arcturus Therapeutics Holdings Inc.ARCT | Director, 10% owner | 4 | 2020-05-20 | 2020-12-09 |
Transactions: 6
Every transaction reported, newest first, including grants, exercises and derivative securities. Purchases and sales (codes P and S) are open-market trades. The reported price is as stated on the form.
What these mean: insiders, Form 4, transaction codes, Rule 10b5-1 plans.
| Date | Company | Transaction | Shares | Reported price | Value | Filing |
|---|---|---|---|---|---|---|
| 2021-08-11 | Arcturus Therapeutics Holdings Inc.Director | Sale | 75,000 | $45.83 | $3.4m | Form 4 |
| 2021-08-10 | Arcturus Therapeutics Holdings Inc.Director | Sale | 725,000 | $55.44 | $40.2m | Form 4 |
| 2020-12-09 | Arcturus Therapeutics Holdings Inc.Director, 10% owner | Sale | 357,745 | $94.97 | $34.0m | Form 4 |
| 2020-12-08 | Arcturus Therapeutics Holdings Inc.Director, 10% owner | Sale | 442,255 | $105.54 | $46.7m | Form 4 |
| 2020-05-20 | Arcturus Therapeutics Holdings Inc.Director, 10% owner | Option exerciseOption (Right to Buy) | 600,000 | $0.00 | $0 | Form 4 |
| 2020-05-20 | Arcturus Therapeutics Holdings Inc.Director, 10% owner | Option exercise | 600,000 | $16.00 | $9.6m | Form 4 |
Source: SEC EDGAR, Forms 4. Last ingested by Listed: Nov 1, 2026, 09:45 ET. Listed shows no prices and gives no investment advice.